Phase 1 Dexlansoprazole Delayed-Release Capsules for Acid-Related Disorders in Infants Aged 1 to 11 Months

NCT02442752 | Withdrawn Phase 1 FDA Drug

• 4 other identifiers: TAK-390MR_1082014-001642-16U1111-1162-4853153300410A0065
• Study Type: interventional
• Target: N/A
• Locations: 5 countries
• Sites: 22

Brief Summary

The purpose of this study is to assess the pharmacokinetics (PK) and pharmacodynamics (PD) \[after daily administration for 7 days\] and safety \[after daily administration for 8 weeks\] of dexlansoprazole in pediatric participants aged 1 to 11 months, inclusive, with acid-related diseases.

Conditions

Pediatric Gastroesophageal Reflux Disease

Keywords

Drug therapy

Outcome Measures

Primary Outcomes (8)

• Maximum Observed Plasma Concentration (Cmax) of Dexlansoprazole

  Maximum observed plasma concentration (Cmax) is the peak plasma concentration of a drug after administration, obtained directly from the plasma concentration-time curve.

  Confinement Day 1 (Between Day 5 and Day 9) Pre-dose, and at multiple timepoints (up to 12 hours) post-dose

• Area Under the Plasma Concentration-Time Curve from Time 0 to the Time of the Last Quantifiable Concentration (AUCt) of Dexlansoprazole

  Area under the plasma concentration versus time curve from time zero to the time of the last quantifiable concentration.

  Confinement Day 1 (Between Day 5 and Day 9) Pre-dose, and at multiple timepoints (up to 12 hours) post-dose

• Area Under the Plasma Concentration-Time Curve From Time 0 to Time tau [AUCtau)] for Dexlansoprazole

  Area under the plasma concentration-time curve from time 0 to time tau, where tau is the length of the dosing interval.

  Confinement Day 1 (Between Day 5 and Day 9) Pre-dose, and at multiple timepoints (up to 12 hours) post-dose

• Dose Normalized Maximum Observed Plasma Concentration (Cmax/dose) of Dexlansoprazole

  Dose normalized maximum observed plasma concentration (Cmax/dose) is the peak plasma concentration of a drug after administration obtained directly from the plasma concentration-time curve, divided by the administered dose in milligrams.

  Confinement Day 1 (Between Day 5 and Day 9) Pre-dose, and at multiple timepoints (up to 12 hours) post-dose

• Dose Normalized Area Under the Plasma Concentration-Time Curve from Time 0 to the Time of the Last Quantifiable Concentration (AUCt/dose) of Dexlansoprazole

  Area under the plasma concentration versus time curve from time zero to the time of the last quantifiable concentration divided by the administered dose in milligrams.

  Confinement Day 1 (Between Day 5 and Day 9) Pre-dose, and at multiple timepoints (up to 12 hours) post-dose

• Dose Normalized Area Under the Plasma Concentration-Time Curve from Time 0 to the Time of the Last Quantifiable Concentration (AUCt/dose) of Dexlansoprazole

  Area under the plasma concentration-time curve during a dosing interval, where tau is the length of the dosing interval, divided by the administered dose in milligrams.

  Confinement Day 1 (Between Day 5 and Day 9) Pre-dose, and at multiple timepoints (up to 12 hours) post-dose

• Change from Baseline in Percent of Time with Intragastric pH>4

  Intragastric pH will be measured approximately every 2 to 4 seconds, based on the pH recorder used for the measurement, for a 24-hour period. Fifteen minute medians are calculated and the percent of time pH is greater than 4 is calculated for the 24 hour period.

  Baseline and Confinement Day 1(Between Day 5 and Day 9) [up to 24 hours post-dose]

• Change from Baseline in Mean 24-Hour Intragastric pH

  Intragastric pH will be measured approximately every 2 to 4 seconds, based on the pH recorder used for the measurement, for a 24-hour period. Fifteen minute medians are calculated and the mean pH is calculated for the 24 hour period.

  Baseline and Confinement Day 1(Between Day 5 and Day 9) [up to 24 hours post-dose]

Study Arms (4)

Regimen A: Dexlansoprazole 10 mg

EXPERIMENTAL

Dexlansoprazole 10 mg, delayed-release capsules, orally, once daily for 8 weeks.

Drug: Dexlansoprazole

Regimen B: Dexlansoprazole 15 mg

EXPERIMENTAL

Dexlansoprazole 15 mg, delayed-release capsules, orally, once daily for 8 weeks.

Drug: Dexlansoprazole

Regimen C: Dexlansoprazole 20 mg

EXPERIMENTAL

Dexlansoprazole 20 mg, delayed-release capsules, orally, once daily for 8 weeks.

Drug: Dexlansoprazole

Regimen D: Dexlansoprazole 30 mg

EXPERIMENTAL

Dexlansoprazole 30 mg, delayed-release capsules, orally, once daily for 8 weeks.

Drug: Dexlansoprazole

Interventions

Dexlansoprazole DRUG

Dexlansoprazole capsules

Also known as: TAK-390MR

Regimen A: Dexlansoprazole 10 mg; Regimen B: Dexlansoprazole 15 mg; Regimen C: Dexlansoprazole 20 mg; Regimen D: Dexlansoprazole 30 mg

Eligibility Criteria

• Age: 1 Month - 11 Months
• Sex: all
• Healthy Volunteers: No
• Age Groups: Child (0-17)

You may qualify if:

• Prior to any study-specific procedures being performed and after having the study fully explained and all questions answered, the informed consent form (ICF) must be signed and dated by parent(s) or legal guardian(s). The Screening Period starts at the time of consent.
• Is a male or female infant 1 to 11 months old, inclusive, on Day 1. Infants who were born prematurely must be ≥ 45 weeks old based on corrected gestational age.
• At the Initial Screening and Day -1 visits, participant must have body weight percentile-for-age within the 5th through 95th percentile by age, inclusive, as determined by the World Health Organization (WHO) growth chart.
• Must be ≥ 3.4 kg at the Screening and Day -1 visits.
• Participants who take a prescription or nonprescription proton pump inhibitor (PPI), histamine-2 receptor antagonists(H2RA), sucralfate, or antacids on a regular or as required basis must agree to discontinue use at Day -1 (except cimetidine, which must be discontinued 28 days prior to Day -1) or other acid suppression therapy, and agree to discontinue use throughout the study.
• Must have endoscopically proven erosive esophagitis (EE), a history of EE, and/or 1 or more of the following underlying conditions that predispose the participant to chronic gastroesophageal reflux disease (GERD) and EE: moderate to severe neurologic impairment, repaired esophageal atresia, hiatal hernia, cystic fibrosis, bronchopulmonary dysplasia, or end-stage renal disease.
• Except for participants with EE, a history of EE, or repaired esophageal atresia, participants have:
• Received prior PPI therapy or other acid suppression therapy for a minimum of 2 weeks during any time in the past with symptomatic response and have demonstrated a recurrence of symptoms following at least 1 attempted withdrawal of PPI therapy or other acid suppression therapy AND
• Have undergone esophageal pH monitoring in the recent past to document that their symptoms are due to acid-mediated disease.
• Must be able to ingest study medication granules sprinkled on 1 tablespoon of applesauce or pureed apples, or as a mixture of granules in water administered via an oral syringe.
• Must be at least 7 days post-surgery by dosing on Day 1 and have no anticipated need for surgery during the study.
• Screening laboratory samples must be collected Day -7 to Day -2) and the results must be within the range expected for this infant population (except gastrin results as those results will be available after Day 1). The laboratory results should indicate no clinically significant (CS) abnormality in chemistry (including electrolytes, blood urea nitrogen \[BUN\]), creatinine, glucose, alanine aminotransferase (ALT), aspartate aminotransferase (AST), and total bilirubin), hematology (complete blood cell count, including differential), and urinalysis parameters (if standard of care).

You may not qualify if:

• Has known history of or current presence of peptic ulcers or gastrointestinal bleeding (hematemesis, hematochezia).
• Has poor venous access or any contraindication to blood sampling.
• Has known history of eosinophilic gastroenteropathy, or a coexisting disease affecting the esophagus, including esophageal varices, viral or fungal infection, or esophageal stricture, history of radiation therapy or cryotherapy to the esophagus, and caustic or physiochemical trauma such as sclerotherapy to the esophagus.
• Has active malabsorption syndrome, cow's milk intolerance, milk protein allergy, or celiac disease.
• Has any finding in his/her medical history, physical examination, or safety clinical laboratory tests giving reasonable suspicion of a disease that might interfere with the conduct of the study or that would contraindicate taking dexlansoprazole delayed-release capsules or a similar drug in the same class (ie, a PPI).
• Has a known hypersensitivity to any PPI or any component of the formulation of dexlansoprazole delayed-release capsules.
• Is required to take excluded medications or it is anticipated that the participant will require treatment with at least 1 of the disallowed concomitant medications during the study evaluation period.
• Has a history of malignant disease.
• Has a known history of infection with the human immunodeficiency virus.
• Has lost \> 10% of the total blood volume, undergone plasmapheresis, or has had a transfusion of any blood product within 90 days prior to the first dose of study medication.
• Has consumed Excluded Medications and Dietary Products during the time periods listed, or parent(s) or legal guardian(s) is unwilling to agree to participant abstaining from products while participating in the study.
• Has participated in a study of an investigational agent (including dosing or follow-up) within 30 days prior to Screening.
• Has a Screening Visit laboratory value that the principal investigator and sponsor consider to be clinically significant.
• Has creatinine \> 1.5 mg/dL, ALT and/or AST \> 2 times the upper limit of normal (ULN), or total bilirubin \> 2.0 mg/dL with AST/ALT elevated above the limits of normal values.
• The participant or parent/legal guardian is an immediate family member, study site employee, or is in a dependent relationship with a study site employee who is involved in the conduct of this study or may consent under duress.

Sponsors & Collaborators

• Takeda: lead

Study Sites (22)

Children's Hospital Los Angeles

Los Angeles, California, 90027, United States

Location

University of Louisville

Louisville, Kentucky, 40202, United States

Location

Johns Hopkins University School Of Medicine

Baltimore, Maryland, 21218, United States

Location

Michigan Pediatric GI Center

Flint, Michigan, 48532, United States

Location

Promedica Toledo Children's Hospital

Toledo, Ohio, 43606, United States

Location

Cook Children's Medical Center

Fort Worth, Texas, 76104, United States

Location

Hadassah University Hospital - Ein Kerem

Jerusalem, 9112001, Israel

Location

Schneider Children's Medical Center

Petah Tikva, 4920235, Israel

Location

Sheba Medical Center

Ramat Gan, 5262000, Israel

Location

Assaf Harofeh M.C

Rishon LeZiyyon, 75309, Israel

Location

Azienda Ospedaliera Universitaria "Federico II"

Napoli, 80131, Italy

Location

Umberto I Pol. di Roma-Universita di Roma La Sapienza

Roma, 00161, Italy

Location

Ospedale Pediatrico Bambino Gesu

Roma, 00165, Italy

Location

Policlinico Universitario Agostino Gemelli

Roma, 00168, Italy

Location

Centro de Investigacion Clinica Acelerada, S.C.

Mexico City, Mexico City, 07020, Mexico

Location

Centro de Investigacion Clinica Chapultepec S.A. de C.V.

Morelia, Michoacán, 58260, Mexico

Location

Accelerium S. de R.L. de C.V.

Monterrey, Nuevo León, 64000, Mexico

Location

Szpital Uniwersytecki nr 2 im.dr J. Biziela

Bydgoszcz, 85-168, Poland

Location

Uniwersytecki Szpital Dzieciecy w Krakowie

Krakow, 30-663, Poland

Location

Uniwersytecki Szpital Dzieciecy w Lublinie

Lublin, 20-093, Poland

Location

Szpital Wojewodzki nr 2 w Rzeszowie

Rzeszów, 35-301, Poland

Location

Instytut "Pomnik - Centrum Zdrowia Dziecka"

Warsaw, 04-730, Poland

Location

MeSH Terms

Interventions

Dexlansoprazole

Intervention Hierarchy (Ancestors)

Lansoprazole; 2-Pyridinylmethylsulfinylbenzimidazoles; Sulfoxides; Sulfur Compounds; Organic Chemicals; Pyridines; Heterocyclic Compounds, 1-Ring; Heterocyclic Compounds; Benzimidazoles; Heterocyclic Compounds, 2-Ring; Heterocyclic Compounds, Fused-Ring

Study Officials

• Medical Director Clinical Science

  Takeda

  STUDY DIRECTOR

Study Design

• Study Type: interventional
• Phase: phase 1
• Allocation: RANDOMIZED
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: May 9, 2015
• First Posted: May 13, 2015
• Study Start: June 15, 2025
• Primary Completion: December 23, 2025
• Study Completion: December 23, 2025
• Last Updated: April 15, 2020

Record last verified: 2020-04

Locations

IT (4); IL (4); ME (3); US (6); PL (5)